The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, ...

Analysts have suggested that approval for AAD could swell sales of Rexulti by $500 million to $1 billion, a big step up for a drug which currently makes around $1.4 billion in annual sales.

In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

Abilify contains the active ingredient aripiprazole, while Rexulti contains the active ingredient brexpiprazole. An active ingredient is what makes a medication work. Learn more about Abilify vs.

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease, after it succeeded in three out of four ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

The company is also facing patent expiries for its antidepressant Trintellix/Brintellix (vortioxetine) – for many years its biggest-selling drug – in 2026, while its new top product Rexulti ...

The drug did not show statistical significance ... cognitive and behavioral symptoms such as agitation and aggression. Rexulti contains the FDA's harshest "black-box" warning for increased risk ...